摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-fluoro-4H-chromen-4-one | 75487-85-3

中文名称
——
中文别名
——
英文名称
8-fluoro-4H-chromen-4-one
英文别名
4H-1-Benzopyran-4-one, 8-fluoro-;8-fluorochromen-4-one
8-fluoro-4H-chromen-4-one化学式
CAS
75487-85-3
化学式
C9H5FO2
mdl
——
分子量
164.136
InChiKey
QLGMRIUNTQALNI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    247.8±40.0 °C(Predicted)
  • 密度:
    1.353±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carbohydrazide8-fluoro-4H-chromen-4-one溶剂黄146 作用下, 以 乙醇 为溶剂, 以0.57 g的产率得到
    参考文献:
    名称:
    苯并杂环酰肼腙类化合物及制备方法和杀菌剂应用
    摘要:
    本发明公开了苯并杂环酰腙类化合物及制备方法和杀菌剂应用。具体地,涉及式I所示的化合物,以及所述化合物作为农用杀菌剂的用途。#imgabs0#
    公开号:
    CN117800956A
  • 作为产物:
    描述:
    4-oxochromene-8-diazonium 以54%的产率得到
    参考文献:
    名称:
    ABDEL-MEGEID F. M. E.; EL-KASCHEF M. A. F.; GHATTAS A. A. G., EGYPT. J. CHEM., 1977(1980), 20, NO 5, 453-462
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • An Efficient Microwave-Assisted Propylphosphonic Anhydride (T3P®)-Mediated One-Pot Chromone Synthesis via Enaminones
    作者:Manoranjan Behera、C. Balakrishna、Venu Kandula、Ramakrishna Gudipati、Satyanarayana Yennam、P. Devi
    DOI:10.1055/s-0036-1591898
    日期:2018.5
    An efficient synthesis of 4H-chromene-4-ones via enamino ketones, with cyclization by using T3P® under microwave heating is described. This is the first report for the synthesis of chromones by using T3P®. Significant features of this method include short reaction times and high-purity products.
    描述了通过烯氨基酮有效合成 4H-色烯-4-酮,并在微波加热下使用 T3P® 环化。这是使用 T3P® 合成色酮的第一份报告。该方法的显着特点包括反应时间短和产品纯度高。
  • [EN] SUBSTITUTED CHROMANES AND METHOD OF USE<br/>[FR] CHROMANES SUBSTITUÉS ET MÉTHODE D'UTILISATION
    申请人:ABBVIE INC
    公开号:WO2016069757A1
    公开(公告)日:2016-05-06
    The invention provides for compounds of formula (I), wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R" have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    该发明提供了一种公式(I)化合物,其中R1、X、Y、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、m和R"具有规范中定义的任何值,以及其药学上可接受的盐,这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的,包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个公式(I)化合物组成的药物组合物。
  • SUBSTITUTED CHROMANES AND METHOD OF USE
    申请人:AbbVie Inc.
    公开号:US20160120841A1
    公开(公告)日:2016-05-05
    The invention provides for compounds of formula (I) wherein R 1 , X, Y, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    本发明提供了以下式子(I)的化合物,其中R1、X、Y、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、m和R″的任何一个取值均符合规范要求,并且其药学上可接受的盐,在治疗由CFTR介导和调节的疾病和病状中具有作用,包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式(I)化合物组成的制药组合物。
  • ABDEL-MEGEID F. M. E.; EL-KASCHEF M. A. F.; GHATTAS A. A. G., EGYPT. J. CHEM., 1977(1980), 20, NO 5, 453-462
    作者:ABDEL-MEGEID F. M. E.、 EL-KASCHEF M. A. F.、 GHATTAS A. A. G.
    DOI:——
    日期:——
  • Substituted Chromanes and Method of Use
    申请人:AbbVie S.à.r.l.
    公开号:US20190127356A1
    公开(公告)日:2019-05-02
    The invention provides for compounds of formula (I) wherein R 1 , X, Y, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
查看更多